FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

McCarthy Christopher		 2. Date of Event Requiring Statement (MM/DD/YYYY)
4/21/2023 

 3. Issuer Name and Ticker or Trading Symbol

INTERPACE BIOSCIENCES, INC. [IDXG]
(Last)        (First)        (Middle)

C/O INTERPACE BIOSCIENCES, INC., 300 INTERPACE PARKWAY; BLDG C, 1ST FLOOR		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Principal Financial Officer /
(Street)

PARSIPPANY, NJ 07054      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 7310 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)  (1)3/10/2031 Common Stock 2500 $6.00 D  
Restricted Stock Units  (2) (2)Common Stock 5000 $0.00 D  
Explanation of Responses:
(1) One-third of the options will vest and become exercisable on 3/10/2022, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of April 2022, subject to continued employment through each such vesting date.
(2) One-third of the restricted stock units will vest commencing on December 1, 2022 and the remaining two-thirds will vest in equal yearly installments thereafter for the next two years.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
McCarthy Christopher
C/O INTERPACE BIOSCIENCES, INC.
300 INTERPACE PARKWAY; BLDG C, 1ST FLOOR
PARSIPPANY, NJ 07054

Principal Financial Officer
Signatures
/s/ Christopher McCarthy5/3/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Interpace Biosciences (QX) (USOTC:IDXG)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025 Click aqui para mais gráficos Interpace Biosciences (QX).
Interpace Biosciences (QX) (USOTC:IDXG)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025 Click aqui para mais gráficos Interpace Biosciences (QX).